Reducing mortality from 2019-nCoV: host-directed therapies should be an option

Affiliations

¹ Department of Infection, Division of Infection and Immunity, University College London, London, UK; National Institute for Health Research Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK.
² Department of Medicine & Therapeutics, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, China.
³ Special Infectious Agents Unit, King Fahd Medical Research Center and Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
⁴ Infectious Diseases Division, Department of Medicine and Research Department, Prince Mohamed Bin Abdulaziz Hospital, Ministry of Health, Riyadh, Saudi Arabia; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
⁵ Immunotherapy Programme, Champalimaud Centre for the Unknown, 1400-038 Lisbon, Portugal; I Med Clinic, University of Mainz, Mainz, Germany. Electronic address: markus.maeurer@fundacaochampalimaud.pt.

Alimuddin Zumla et al. Lancet. 2020.

. 2020 Feb 22;395(10224):e35-e36.

doi: 10.1016/S0140-6736(20)30305-6. Epub 2020 Feb 5.

¹ Department of Infection, Division of Infection and Immunity, University College London, London, UK; National Institute for Health Research Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK.
² Department of Medicine & Therapeutics, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, China.
³ Special Infectious Agents Unit, King Fahd Medical Research Center and Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
⁴ Infectious Diseases Division, Department of Medicine and Research Department, Prince Mohamed Bin Abdulaziz Hospital, Ministry of Health, Riyadh, Saudi Arabia; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
⁵ Immunotherapy Programme, Champalimaud Centre for the Unknown, 1400-038 Lisbon, Portugal; I Med Clinic, University of Mainz, Mainz, Germany. Electronic address: markus.maeurer@fundacaochampalimaud.pt.

No abstract available

References

1. WHO Novel coronavirus (2019-nCoV) situation report - 14. Feb 3, 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/2...
1. Hui DSC, Zumla A. Severe acute respiratory syndrome: historical, epidemiologic, and clinical features. Infect Dis Clin North Am. 2019;33:869–889. - PMC - PubMed
1. Azhar EI, Hui DSC, Memish ZA, Drosten C, Zumla A. The Middle East respiratory syndrome (MERS) Infect Dis Clin North Am. 2019;33:891–905. - PMC - PubMed
1. Huang C, Wang Y, Li X. Clinical features of patients infected with 2019 coronavirus in Wuhan, China. Lancet. 2020 doi: 10.1016/S0140-6736(20)30183-5. published online Jan 24. - DOI - PMC - PubMed
1. Li G, Fan Y, Lai Y. Coronavirus infections and immune responses. J Med Virol. 2020 doi: 10.1002/jmv.25685. published online Jan 25. - DOI - PMC - PubMed